NAMUR, Belgium, November 5, 2014 /PRNewswire/ — VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that its Chief Executive Officer, Cameron Reynolds, is scheduled to present at the SeeThruEquity Fall Microcap Investor Conference being held November 12, 2014 in New York. The conference is attended by public companies, institutional investors, industry executives, private equity firms, private companies, venture capitalists, business development executives and sophisticated private investors.
Mr. Reynolds will present on Wednesday, November 12, 2014 at 9:00 a.m. ET. During his presentation, he plans to discuss the Company’s latest developments, including initial data analysis from its 4,800-subject colorectal cancer study, which was announced last month at the International Conference of Anticancer Research in Europe.
Preliminary analysis of the study data suggests that the Company’s NuQ® blood-based diagnostic test is able to correctly diagnose approximately 84% of colorectal cancers, detect both early (I or II) and late (III or IV) stage cases with high accuracy and identify the majority of colorectal cancers as being either colon or rectal cancers (i.e., distinguish between the cancer types).
Details of the presentation are as follows:
Wednesday, November 12, 2014
9:00 a.m. ET
Convene Midtown East in New York, New York.
Persons attending the Conference who would like to schedule a 1-on-1 meeting with VolitionRx management during the conference may do so by contacting Amit Tandon at email@example.com or Lee Roth of The Ruth Group at firstname.lastname@example.org.
For those unable to attend, a live webcast of Mr. Reynolds’ presentation will be available at http://wsw.com/webcast/seethru9/vnrx and on the Company’s website at www.volitionrx.com. Following his presentation, this webcast will be archived for 90 days.
About SeeThruEquity, LLC
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The Company’s research is not paid for and unbiased as it does not conduct any investment banking or commission based business. SeeThruEquity’s research is contributed to by Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distributed to its opt-in investors along with Thomson Estimates, the leading estimates platform on Wall Street.
SeeThruEquity Conferences are held approximately every quarter throughout the year and host approximately 2500 industry professionals and investors who are looking for new ideas, opportunities, and corporate relationships. For more information, visit www.seethruequity.com.
VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.
VolitionRx’s goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx’s research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.
Charlotte Reynolds, VolitionRx
Telephone: +44 (0) 795 217 7498
Kirsten Thomas, The Ruth Group
Telephone: +1 (646) 536-7014
Scott Powell, Investor Relations
Telephone: +1 (646) 650-1351
Lee Roth, The Ruth Group
Telephone: +1 (646) 536-7012
Safe Harbor Statement
Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests” and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company’s blood-based diagnostic test as well as the Company’s ability to develop and successfully commercialize such test platform for early detection of cancer. The Company’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company’s development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company’s intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.